A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors

被引：0
|
作者：
Gupta, Sudeep
Jain, Minish Mahendra
Maru, Anish
Nag, Shona Milon
Somani, Naresh
Mehta, Ajay O.
Kulkarni, Sujay
Acharya, Shivani Anil
Dhobe, Poornima
Jadhav, Nitin
机构：
[1] Tata Mem Hosp, Bombay, Maharashtra, India
[2] Ruby Hall Clin, Pune, Maharashtra, India
[3] SEAROC Canc Ctr, Jaipur, Rajasthan, India
[4] Jehangir Clin Trials Dev Ctr, Pune, Maharashtra, India
[5] Bhagwan Mahaveer Canc Hosp & Res Ctr, Jaipur, Rajasthan, India
[6] Cent India Canc Res Inst, Nagpur, Maharashtra, India
[7] Piramal Healthcare Ltd, Bombay, Maharashtra, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity
    Joshi, Kalpana S.
    Padgaonkar, Amol
    Rathos, Maggie
    Wagh, Vilas
    Manohar, Sonal
    Bhatia, Dimple
    Damre, Anagha
    Sivakumar, Meenakshi
    Sharma, Somesh
    CANCER RESEARCH, 2012, 72
  • [2] A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms: final report
    Hirte, H.
    Digumarti, R.
    Baetz, T.
    Hotte, S.
    Rajappa, S.
    Lacobucci, A.
    Moretto, P.
    Sharma, S.
    Parikh, H.
    Kulkarni, S.
    Patil, S.
    Padigaru, M.
    Kothekar, M.
    Porter, W.
    CANCER RESEARCH, 2009, 69
  • [3] A phase 1 study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms
    Hirte, H. W.
    Raghunadharao, D.
    Baetz, T.
    Hotte, S.
    Rajappa, S.
    Iacobucci, A.
    Sharma, S.
    Parikh, H.
    Kulkarni, S.
    Patil, S.
    Gaston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms
    Hirte, H. W.
    Raghunadharao, D.
    Baetz, T.
    Hotte, S.
    Rajappa, S.
    Lacobucci, A.
    Sharma, S.
    Parikh, H.
    Kulkarni, S.
    Patil, S.
    Padigaru, M.
    Gaston, S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3371S - 3371S
  • [5] Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Schwartz, GK
    O'Reilly, E
    Ilson, D
    Saltz, L
    Sharma, S
    Tong, W
    Maslak, P
    Stoltz, M
    Eden, L
    Perkins, P
    Endres, S
    Barazzoul, J
    Spriggs, D
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2157 - 2170
  • [6] A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
    Mahadevan, D.
    Plummer, R.
    Squires, M. S.
    Rensvold, D.
    Kurtin, S.
    Pretzinger, C.
    Dragovich, T.
    Adams, J.
    Lock, V.
    Smith, D. M.
    Von Hoff, D.
    Calvert, H.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2137 - 2143
  • [7] Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma
    Diab, Adi
    Martin, Alison
    Simpson, Lauren
    Algazi, Alain Patrick
    Chawla, Purvi
    Kim, Dae Won
    Santra, Sourav
    Patel, Vruti
    Jadhav, Nitin
    Abhyankar, Dhiraj
    Davies, Michael A.
    Buch, Shama C.
    Kim, Kevin
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
    Schwartz, GK
    Ilson, D
    Saltz, L
    O'Reilly, E
    Tong, W
    Maslak, P
    Werner, J
    Perkins, P
    Stoltz, M
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) : 1985 - 1992
  • [9] A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.
    Hao, Desiree
    Chu, Quincy
    Welch, Stephen
    Yau, Cindy Y. F.
    Spratlin, Jennifer L.
    Tang, Patricia
    MacKenzie, Mary J.
    Townsley, Carol A.
    Arndt, Diane
    Johnson, Laureen
    Trapsa, Daniela
    Degendorfer, Pamela
    Kulkarni, Sujay
    Jawlekar, Gajendra
    Dhobe, Poornima
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors
    Garralda, Elena
    Schram, Alison M.
    Bedard, Philippe L.
    Schwartz, Gary K.
    Yuen, Eunice
    McNeely, Samuel C.
    Ribeiro, Silvia
    Cunningham, Jason
    Wang, Yi
    Urunuela, Arantxa
    Xu, Xiaojian
    LoRusso, Patricia
    ONCOLOGIST, 2024, 29 (01): : e131 - e140
12345